logo
Plus   Neg
Share
Email

Amgen Drug Shrinks 54% Of Lung Cancer Tumors In Study

Amgen (AMGN) announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. Thirteen of the evaluable patients received the target dose of 960 mg once daily, of which seven (54%) achieved a partial response at one or more timepoints and six (46%) achieved stable disease, for a disease control rate of 100%.

AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein.

The company noted that the additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Tesla Motors Inc. (TSLA) surged 12% in extended trading session on Wednesday after the luxury electric car maker reported a surprise third-quarter profit, which trumped Wall Street estimates. Looking forward, the company said it is "highly confident" to exceed 360,000 deliveries this year. Palo... Spotify is offering free Google Home Mini speakers to all new and existing Spotify Premium users in the U.S. The music streaming service said Tuesday that the Google Home Mini offer is for all eligible Premium Individual and Premium Family master account users in the U.S. The offer is available through November 15, or until supplies last. Federal Cartridge recalled about 3,100 units of Blackhawk T-Series L2C gun holsters due to injury hazard, a statement published by the U.S. Consumer Product Safety Commission said. The safety switch on the firearm can change its position without the knowledge of the user due to the holster design, causing the gun to fire if the trigger is pulled and pose injury hazard to the user and bystander.
Follow RTT
>